Effect of estrogen on the connective tissue of skin in rats.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J Arata.
Explore the source record for details and available documents.
In rat skin of both sexes, significantly higher concentrations of mast cells were observed in the genital area as compared with the skin of the back. The hydroxyproline (HPL) value in the preputial skin was half that in the dorsal skin. The influence of castration and the administration of testosterone on male rat skin mast cells and HPL were investigated. A possible relationship was pointed out between HPL value and the mast cell population of the skin.
1. MIC against 20 strains of staphylococcus isolated from skin infections was studied. MIC was less than or equal to 0.05 mug/ml in 11 strains and greater than 100 mug/ml in 9 strains. 2. Clindamycin-2-phosphate was injected intramuscularly to rats at the dosis of 10 mg/kg in solution of 10 mg/ml. The serum and skin levels of this drug were determined at 0.5, 1, 2, 4 and 7 hours. Mean serum levels of 4 rats were 0.893, 0.578, 0.463, 0.268 and 0.167 mug/ml respectively at 0.5, 1, 2, 4 and 7 hours. The corresponding skin levels were 0.500, 0.707, 0.431, 0.313 and 0.269 mug/g. 3. Clindamycin-2-phosphate was used clinically in 7 patients of skin infection with the following result: excellent in 2 cases, fair in 3 cases and poor in 2 cases. Abdominal pain was complained in one case and loose stool in one case.
Explore the source record for details and available documents.
A patient suffering from recurrent ulcers on the legs was found to excrete large amounts of iminodipeptides in the urine. Among the iminodipeptides excreted, Glu-Hyp, Asp-Pro, Glu-Pro, Leu-Hyp, Gly-Pro, Thr-Pro, Ser-Pro, Ala-Pro, Val-Pro, Ile-Pro, Leu-Pro, and Phe-Pro were identified and their quantities estimated. Some of the iminopeptides had to be synthesized for purposes of identification.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.